Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Sundahl N, De Wolf K, Rottey S, Decaestecker K, De Maeseneer D, Meireson A, Goetghebeur E, Fonteyne V, Verbeke S, De Visschere P, Reynders D, Van Gele M, Brochez L, Ost P. Sundahl N, et al. Among authors: verbeke s. J Transl Med. 2017 Jun 29;15(1):150. doi: 10.1186/s12967-017-1251-3. J Transl Med. 2017. PMID: 28662677 Free PMC article. Clinical Trial.
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial.
Buelens S, Poelaert F, Dhondt B, Fonteyne V, De Visschere P, Ost P, Verbeke S, Villeirs G, De Man K, Rottey S, Decaestecker K, Lumen N. Buelens S, et al. Among authors: verbeke s. Urol Oncol. 2018 Apr;36(4):158.e13-158.e20. doi: 10.1016/j.urolonc.2017.12.009. Epub 2018 Jan 12. Urol Oncol. 2018. PMID: 29336978 Clinical Trial.
Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma.
Sundahl N, Vandekerkhove G, Decaestecker K, Meireson A, De Visschere P, Fonteyne V, De Maeseneer D, Reynders D, Goetghebeur E, Van Dorpe J, Verbeke S, Annala M, Brochez L, Van der Eecken K, Wyatt AW, Rottey S, Ost P. Sundahl N, et al. Among authors: verbeke s. Eur Urol. 2019 May;75(5):707-711. doi: 10.1016/j.eururo.2019.01.009. Epub 2019 Jan 19. Eur Urol. 2019. PMID: 30665814 Clinical Trial.
Vulvar pagetoid urothelial intraepithelial neoplasia: a case report.
Boret S, Lambert E, Charles VP, Philippe T, Ponette D, Darras J, Mattelaer P, Verbeke S, Lumen N, Decaestecker K. Boret S, et al. Among authors: verbeke s. Acta Chir Belg. 2023 Apr;123(2):174-177. doi: 10.1080/00015458.2021.1940442. Epub 2021 Jul 9. Acta Chir Belg. 2023. PMID: 34134597
The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry.
Lumen N, De Bleser E, Buelens S, Verla W, Poelaert F, Claeys W, Fonteyne V, Verbeke S, Villeirs G, De Man K, Rottey S, Van Praet C, Decaestecker K, Ost P; LoMP Registry Investigators. Lumen N, et al. Among authors: verbeke s. Eur Urol Open Sci. 2021 Jun 5;29:68-76. doi: 10.1016/j.euros.2021.05.006. eCollection 2021 Jul. Eur Urol Open Sci. 2021. PMID: 34337536 Free PMC article.
Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
Verghote F, Poppe L, Verbeke S, Dirix P, Albersen M, De Meerleer G, Berghen C, Ost P, Villeirs G, De Visschere P, De Man K, De Maeseneer D, Rottey S, Van Praet C, Decaestecker K, Fonteyne V. Verghote F, et al. Among authors: verbeke s. BMC Cancer. 2021 Oct 18;21(1):1113. doi: 10.1186/s12885-021-08861-x. BMC Cancer. 2021. PMID: 34663254 Free PMC article. Clinical Trial.
Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial.
Fonteyne V, Dirix P, Van Praet C, Berghen C, Albersen M, Junius S, Liefhooghe N, Noé L, De Meerleer G, Ost P, Villeirs G, Verbeke S, De Maeseneer D, Rammant E, Verghote F, Elhaseen E, De Man K, Decaestecker K. Fonteyne V, et al. Among authors: verbeke s. Eur Urol Focus. 2022 Sep;8(5):1238-1245. doi: 10.1016/j.euf.2021.11.004. Epub 2021 Dec 8. Eur Urol Focus. 2022. PMID: 34893458 Free article. Clinical Trial.
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, Bentzen SM, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, Tran PT. Deek MP, et al. Among authors: verbeke s. J Clin Oncol. 2022 Oct 10;40(29):3377-3382. doi: 10.1200/JCO.22.00644. Epub 2022 Aug 24. J Clin Oncol. 2022. PMID: 36001857 Free PMC article.
Evaluating the Impact of Prostate Only Versus Pelvic Radiotherapy for Pathological Node-positive Prostate Cancer: First Results from the Multicenter Phase 3 PROPER Trial.
Fonteyne V, Van Praet C, Ost P, Van Bruwaene S, Liefhooghe N, Berghen C, De Meerleer G, Vanneste B, Verbaeys C, Verbeke S, Lumen N. Fonteyne V, et al. Among authors: verbeke s. Eur Urol Focus. 2023 Mar;9(2):317-324. doi: 10.1016/j.euf.2022.09.005. Epub 2022 Sep 23. Eur Urol Focus. 2023. PMID: 36154809 Free article. Clinical Trial.
100 results